Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

AlphaQuest LLC reduced its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 35.9% in the ...

Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication. "We at Zealand Pharma are acutely aware of the significant unmet medical need for newborns and children with ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Afrin and Flonase are over-the-counter nasal sprays. Learn how they compare in effectiveness, side effects, and safety to ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...